SYPHILIS AND HIV INFECTION
Some special sts recommend additional treatments for early syphilis (e.g., benzath ne pen cillin G administered at 1-week s for 3 weeks, as recommended for late syphilis).
Because CSF abnormal ties (e.g., mononuclear pleocytosis evated protein levels) are common in patients w th early syphilis and in persons w th HIV infection, the clinical and prognostic significance of such CSF abnormalities in HIV infected persons w th primary or secondary syphilis is unknown. Although the major ty of HIV-infected persons respond appropriate y to standard benzathine penicillin G therapy, some specialists recommend intensified therapy when CNS syphilis is suspected in these persons. Therefore, some specialists recommend CSF examination before treatment of HIV-infected persons w th early syphilis, th follow-up CSF examination conducted after treatment in persons w th initial abnormalities.
HIV-infected persons who meet the criteria for treatment failure (i.e., signs or symptoms that persist or recur or persons who have fourfold increase in nontreponemal test titer) should be managed in the same manner as HIVnegative patients (i.e., a CSF examination and re-treatment). CSF examination and retreatment also should be strongly considered for persons whose nontreponema do not decrease fourfold thin 6-12 months of therapy. The majority of specialists wou d re-treat patients w th benzath ne penicillin G administered as 3 doses of 2.4 million units IM each at weekly examinations are normal.
TREATMENT and FOLLOW-UP PRIMARY AND SECONDARY
• • le/forms/ .
• • gender of partners • 3, 6, 9, 12, 24 months: serologic follow-up for those HIV infected
REPORTING and PARTNER MANAGEMENT
• number of partners (new, months from titer at time of treatment.
• Treatment failure: failure of titer to decline fourfold within 6 anonymous, serodiscordant HIV status, exchange of sex for For more on alternative regimens, and for treatments for children and drugs or money) pregnant women, see www.cdc.gov/std/treatment.
• types of sexual exposure • recent STDs; HIV serostatus LATENT
• substance abuse • condom use Early Latent (infection of less than 1 year) Syphilis:
History of syphilis Benzathine penicillin G 2.4 million units IM in a single dose.
• prior syphilis (last serologic test and last treatment) Late Latent (infections of more than 1 year) Syphilis or Latent Physical Exam Syphilis of Unknown Duration:
• oral cavity Benzathine penicillin G 7.2 million units total, administered as 3 doses
• lymph nodes of 2.4 million units IM each at 1-week intervals.
• skin • Sources:
• • http://www.cdc.gov/std/treatment/2006/rr5511.pdf
For more on alternative regimens, treatment for tertiary and neurosyphilis, and for treatments for children and pregnant women, see www.cdc.gov/std/treatment.
• The widely used brand name for benzathine penicillin G is Bicillin L-A
SECONDARY SYPHILIS LATENT SYPHILIS

Continued
PRIMARY SYPHILIS CLINICAL PRESENTATIONS CLINICAL PRESENTATIONS CLINICAL PRESENTATIONS
• Patients who have syphilis and who demonstrate any of the • Lesion appears 2-12 weeks after contact at site of exposure; may
• Symptoms typically occur 6 weeks to 6 months after the chancre • Latent syphilis is defined as seroreactivity without other evidence of following criteria should have a prompt CSF examination: persist for 1-5 weeks then resolves.
appears (can overlap with primary); resolve in 2-10 weeks. disease.
• neurologic or ophthalmic signs or symptoms; • Usually genitorectal but may be extragenital, depending on
• 25% may have relapses of signs and symptoms in first year.
• Patients who have latent syphilis and who acquired syphilis within • evidence of active tertiary syphilis (e.g., aortitis and exposure site.
• Rash (Most common feature, 75-90%): Can be macular, papular, the preceding year are classified as having early latent syphilis. gumma), • Single painless, indurated, clean-based ulcer with rolled edges and squamous (scale), pustular (rare), vesicular (very rare) or • treatment failure; or bilateral painless adenopathy, can mimic herpes and other genital combination; usually nonpruritic; may involve palms and soles (60%).
DIAGNOSTIC ISSUES
• HIV infection with late latent syphilis or syphilis of ulcers.
• Generalized Lymphadenopathy (70-90%): Inguinal, axillary and • Patients' conditions can be diagnosed as early latent syphilis if, unknown duration.
• 25% present with multiple lesions. cervical sites most commonly affected. within the year preceding the evaluation, they had:
• If dictated by circumstances and patient preferences, a CSF • Differential diagnosis: herpes, chancroid, primary HIV ulcers,
• Constitutional Symptoms (50-80%): Malaise, fever. 1. a documented seroconversion or fourfold or greater increase in examination may be performed for patients who do not meet these criteria. trauma and many non-STD causes of genital ulcers.
• Mucous patches (5-30%): Flat gray-white patches on oral and genital mucous membranes.
• Condyloma lata (5-25%): Moist, heaped, wart-like lesions in genital, Darkfield peri-rectal and rectal areas, and oral cavity.
titer of a nontreponemal test; 2. unequivocal symptoms of primary or secondary syphilis; 3. a sex partner documented to have primary, secondary, or early latent syphilis; or
TERTIARY SYPHILIS
4. reactive nontreponemal and treponemal tests from a person whose • ~80% sensitive, varies with experience of the examiner and
• Alopecia (10-15%): Patchy hair loss, loss of lateral eyebrows. decreased sensitivity as lesion ages.
• Neurological (<2%): Visual loss, hearing loss, cranial nerve palsies. only possible exposure occurred within the previous 12 months. Tertiary syphilis refers to gumma and cardiovascular syphilis RPR/USR
• Nontreponemal serologic titers usually are higher during early latent but not to all neurosyphilis. Patients who have symptomatic late • A negative RPR/USR (or VDRL) does not exclude the diagnosis of DIAGNOSTIC ISSUES syphilis than late latent syphilis. However, early latent syphilis syphilis should be given a CSF examination before therapy is syphilis; only ~75-85% sensitive in primary syphilis.
RPR/USR cannot be reliably distinguished from late latent syphilis solely on initiated. Some providers treat all patients who have • Tests must be quantified to the highest titer and titer on the day of • ~100% sensitive in secondary syphilis. the basis of nontreponemal titers. cardiovascular syphilis with a neurosyphilis regimen. treatment must be used to assess treatment response.
• Tests must be quantified to the highest titer and titer on the day of • All patients with latent syphilis should have careful examination of The complete management of patients who have cardiovascular • Always use the same testing method (RPR or USR) in sequential treatment must be used to assess treatment response. all accessible mucosal surfaces (i.e., the oral cavity, the perineum in or gummatous syphilis is beyond the scope of these guidelines. testing; cannot compare titer from the two tests.
• Always use the same testing method (RPR or USR) in sequential women, and perianal area, underneath the foreskin in uncircumcised These patients should be managed in consultation with an • Tests lack specificity (biologic false positive); all reactive tests testing; cannot compare titer from the two tests. men) to evaluate for internal mucosal lesions. infectious diseases specialist. need to be confirmed by a treponemal test for syphilis diagnosis.
• Tests lack specificity (biologic false positive); all reactive tests need • All patients who have syphilis should be tested for HIV infection.
to be confirmed by a treponemal test for syphilis diagnosis.
• All persons who have latent syphilis should be evaluated clinically See www.cdc.gov/std/treatment for more information about tertiary syphilis. CNS involvement can occur during any stage of syphilis. A patient who has clinical evidence of neurologic involvement with syphilis (e.g., cognitive dysfunction, motor or sensory deficits, ophthalmic or auditory symptoms, cranial nerve palsies, and symptoms or signs of meningitis) should have a CSF examination.
See www.cdc.gov/std/treatment for more information about neurosyphilis.
